WO2002048397A3 - Regulation of human adenylate cyclase, type vii - Google Patents

Regulation of human adenylate cyclase, type vii Download PDF

Info

Publication number
WO2002048397A3
WO2002048397A3 PCT/EP2001/014398 EP0114398W WO0248397A3 WO 2002048397 A3 WO2002048397 A3 WO 2002048397A3 EP 0114398 W EP0114398 W EP 0114398W WO 0248397 A3 WO0248397 A3 WO 0248397A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
type vii
adenylate cyclase
caused
syndrome
Prior art date
Application number
PCT/EP2001/014398
Other languages
French (fr)
Other versions
WO2002048397A2 (en
Inventor
Ningshu Liu
Yoshihisa Manabe
Original Assignee
Bayer Ag
Ningshu Liu
Yoshihisa Manabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Ningshu Liu, Yoshihisa Manabe filed Critical Bayer Ag
Priority to AU2002237228A priority Critical patent/AU2002237228A1/en
Publication of WO2002048397A2 publication Critical patent/WO2002048397A2/en
Publication of WO2002048397A3 publication Critical patent/WO2002048397A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

An adenylate cyclase type VII protein, cDNA, and reagents which regulate human adenylate cyclase type VII can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, diseases that are caused by aberrant activity of this enzyme and diseases whose symptoms can be ameliorated by stimulating or inhibiting the activity of type VII adenylyl cyclase. Such diseases include, for example, diseases caused by allergic or inflammatory reaction, such as asthma, allergic rhinitis, atopic dermatitis, food allergy, contact allergy, hives conjunctivitis, vernal catarrh; autoimmune diseases, COPD, inflammatory bowel diseases, rheumatoid arthritis, osteoarthritis, sepsis/septic shock, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease, Suoegren's syndrome, gout; and bacterial, fungal, and viral infections, among others.
PCT/EP2001/014398 2000-12-11 2001-12-07 Regulation of human adenylate cyclase, type vii WO2002048397A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002237228A AU2002237228A1 (en) 2000-12-11 2001-12-07 Regulation of human adenylate cyclase, type vii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25478200P 2000-12-11 2000-12-11
US60/254,782 2000-12-11

Publications (2)

Publication Number Publication Date
WO2002048397A2 WO2002048397A2 (en) 2002-06-20
WO2002048397A3 true WO2002048397A3 (en) 2004-01-08

Family

ID=22965568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014398 WO2002048397A2 (en) 2000-12-11 2001-12-07 Regulation of human adenylate cyclase, type vii

Country Status (2)

Country Link
AU (1) AU2002237228A1 (en)
WO (1) WO2002048397A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087295A1 (en) * 2001-10-31 2003-05-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the treatment and diagnosis of pain disorders using 9805
EP1573055A4 (en) * 2002-09-24 2006-05-10 Univ Colorado Regents Genetic diagnosis of depression
GB0223272D0 (en) * 2002-10-08 2002-11-13 Oxford Glycosciences Uk Ltd A protein involved in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040170A2 (en) * 1996-04-23 1997-10-30 Cadus Pharmaceutical Corporation Functional expression of heterologous adenylyl cyclase
US6107076A (en) * 1995-10-04 2000-08-22 Board Of Regents, The University Of Texas System Soluble mammalian adenylyl cyclase and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107076A (en) * 1995-10-04 2000-08-22 Board Of Regents, The University Of Texas System Soluble mammalian adenylyl cyclase and uses therefor
WO1997040170A2 (en) * 1996-04-23 1997-10-30 Cadus Pharmaceutical Corporation Functional expression of heterologous adenylyl cyclase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEITZ E. ET AL.: "Adenylyl Cyclase Type 7 Is the Predominant Isoform in the Bovine Retinal Pigment Epithelium", ACTA ANATOMICA, vol. 162, no. 2-3, 1998, pages 157 - 162, XP008012572 *
DEFER N. ET AL.: "Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 279, September 2000 (2000-09-01), pages F400 - F416, XP002227423 *
NOMURA N ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. I. THE CODING SEQUENCES OF 40 NEW GENES (KIA A0001-KIA A0040) DEDUCED BY ANALYSIS OF RANDOMLY SAMPLED CDNA CLONES FROM HUMAN IMMATURE MYELOID CELL LINE KG-1", DNA RESEARCH, vol. 1, no. 1, 1994, pages 27 - 35, XP002913067, ISSN: 1340-2838 *
VÖLKEL H. ET AL.: "Cloning and expression of a bovine adenylyl cyclase type VII specific to the retinal pigment epithelium", FEBS LETTERS, vol. 378, 1996, pages 245 - 249, XP002227422 *
WATSON P.A. ET AL.: "Molecular Cloning and Characterization of Type VII Isoform of Mammalian Adenylyl Cyclase Expressed Widely in Mouse Tissues and in S49 Mouse Lymphoma Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 46, 18 November 1994 (1994-11-18), pages 28893 - 28898, XP002227421 *

Also Published As

Publication number Publication date
AU2002237228A1 (en) 2002-06-24
WO2002048397A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
Driscoll et al. Mechanism and regulation of selenoprotein synthesis
Harris et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
PE33495A1 (en) ISOXAZOLINE COMPOUND USEFUL AS AN ANTI-INFLAMMATOR AGENT
WO2003089601A3 (en) 3-deoxyglucosone and skin
WO2003024965A3 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
WO2003078431A8 (en) Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
ES2139754T3 (en) 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS.
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
NO20050917L (en) Thiomolybdate analogues and applications thereof
WO2007146349A3 (en) Cgrp receptor antagonists
WO2007062318A3 (en) Chemical compounds
WO2002048397A3 (en) Regulation of human adenylate cyclase, type vii
WO2005110409A3 (en) Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity
Penning et al. Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A4 hydrolase
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
FI963882A0 (en) Benzothiazole derivatives as inhibitors of 5-lipoxygenase biosynthesis
WO2002074803A3 (en) Regulation of human icos v protein
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2007056996A3 (en) Hypertension agent containing tribomechanically activated zeolites
Suzuki et al. The relationship between sleeping habits and sleeping problems and/or physical discomforts among junior high school students

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP